profit from every $100 of sales.
$0$100
Compass Therapeutics
$0.77-5.63% today
-83.8% in 1 year
1-year low $0.691-year high $6.69
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Compass Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$66.5 million of profit last year.
SalesProfit
Compass Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Compass Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Compass Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 1 | 0 | |
| – | – | – | – | |
| -42 | -50 | -57 | -73 | |
| -40 | -48 | -55 | -71 | |
| -39 | -42 | -49 | -66 | |
| -0.37 | -0.33 | -0.36 | -0.42 | |
| – | – | – | – | |
| – | – | -6,661.8% | – | |
| – | – | -5,808.8% | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 200 | 157 | 140 | 220 |
| Cash | 35 | 24 | 43 | 31 |
| Total debt | 3 | 2 | 7 | 10 |
| Total liabilities | 18 | 8 | 15 | 23 |
| 182 | 149 | 125 | 197 | |
| 105 | 127 | 137 | 158 | |
| -17.8% | -26.5% | -33.9% | -27.8% | |
| -21.6% | -28.6% | -39.4% | -33.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -34 | -41 | -45 | -49 | |
| 0 | 0 | 0 | 0 | |
| -34 | -41 | -45 | -49 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 5 | 6 | 9 | 8 |
Valuation
- –
- –
- –
- 1.9×
- 163.9×
- –
- –
- -32.2%
- -35.4%
- 0.0%
Profitability
- 0.0%
- -6,661.8%
- -5,808.8%
- 0.0%
- -38.3%
- -35.2%
- -39.7%
- -33.2%
- -38.6%
- –
Growth
- –
- –
- −9.5%
- –
- +25.8%
Financial health
- -0.7×
- 0.05
- 4.8%
- –
- 19.04
- 19.04
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 13%of 946
Bottom 2%of 986
What analysts expect
- Average price target
- $11.20
- Range
- $9.00 – $15.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.10 | -0.10 | +0.0% |
| Mar 5, 2026 | -0.09 | -0.10 | +10.0% |
| Nov 5, 2025 | -0.08 | -0.14 | +42.9% |
| Aug 11, 2025 | -0.14 | -0.13 | −7.7% |
| May 8, 2025 | -0.12 | -0.12 | +0.0% |
| Feb 27, 2025 | -0.11 | -0.10 | −10.0% |
| Nov 12, 2024 | -0.08 | -0.11 | +27.3% |
| Aug 12, 2024 | -0.10 | -0.10 | +0.0% |
News
Coinbase Jumps 6% on Compass Point Upgrade Ahead of Senate CLARITY Act Vote; Strategy Climbs 3%, MARA SlipsYahoo Finance · Sep 14, 2026How the private-listing war between Zillow and Compass could cost home buyers and sellersMarketWatch · Aug 28, 2026Outreach Recognized as a Top Partner Program in the World with Ecosystem Compass AwardYahoo Finance · Aug 27, 2026The newest story we have is from Sep 14, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
55No pass
Philip Fisher
32No pass
Peter Lynch
11No pass
Joel Greenblatt
0No pass
Charlie Munger
26No pass
Terry Smith
23No pass
Questions about Compass Therapeutics
Is Compass Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Compass Therapeutics AI analysis
What does Compass Therapeutics do?
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. It is in Biotechnology.
Does Compass Therapeutics pay a dividend?
No. Compass Therapeutics does not pay a dividend at the moment.
Is Compass Therapeutics stock halal?
Questionable. Compass Therapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Compass Therapeutics stock done over the past year?
Down 83.8% over the past twelve months, to $0.77. It traded between $0.69 and $6.69 and is 88.4% below its high.
Who are Compass Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Compass Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.